Research graph
References from Anti–PD-1 Therapy and Long-Term Toxic Effects Among Patients With Melanoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
10.1002/ijc.31937 · 2019 · External reference
Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017.
10.1016/j.ejca.2017.06.028 · 2017 · External reference
Combinatorial approach to cancer immunotherapy: strength in numbers.
10.1189/jlb.5ri0116-013rr · 2016 · External reference
Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma.
10.1056/nejmoa2407417 · 2025 · External reference
Adjuvant pembrolizumab versus IFNa2b or ipilimumab in resected high-risk melanoma.
10.1158/2159-8290.cd-21-1141 · 2022 · External reference
Understanding and treating the inflammatory adverse events of cancer immunotherapy.
10.1016/j.cell.2021.02.011 · 2021 · External reference
Extended follow-up of chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma.
10.1001/jamanetworkopen.2023.27145 · 2023 · External reference
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
10.1016/j.ejca.2023.113354 · 2023 · External reference
Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma.
10.1001/jamaoncol.2021.0051 · 2021 · External reference
Characterizing chronic cutaneous immune-related adverse events following immune checkpoint inhibitors.
10.1001/jamadermatol.2025.0025 · 2025 · External reference
Immune-checkpoint inhibitors: long-term implications of toxicity.
10.1038/s41571-022-00600-w · 2022 · External reference
Recurrence of hypophysitis after immune checkpoint inhibitor rechallenge.
10.1093/oncolo/oyac220 · 2022 · External reference
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
10.1186/s12967-019-02132-x · 2019 · External reference
Dysautonomia associated with immune checkpoint inhibitors.
10.1007/s00415-023-11667-5 · 2023 · External reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.
10.1200/jco.21.01440 · 2021 · External reference
Higher levels of VEGF-A and TNFa in patients with immune checkpoint inhibitor–induced inflammatory arthritis.
10.1186/s13075-025-03546-3 · 2025 · External reference
Predictive biomarkers for checkpoint inhibitor immune-related adverse events.
10.3390/cancers15051629 · 2023 · External reference
Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti–PD-1 antibodies.
10.1111/1346-8138.17183 · 2024 · External reference
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.
10.1136/jitc-2021-003551 · 2022 · External reference
Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis.
10.1186/s12886-024-03575-7 · 2024 · External reference
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
10.1186/s40364-021-00314-8 · 2021 · External reference
Targeting molecular pathways to control immune checkpoint inhibitor toxicities.
10.1016/j.it.2024.11.014 · 2025 · External reference
Long-term side effects of glucocorticoids.
10.1517/14740338.2016.1140743 · 2016 · External reference
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity.
10.1136/jitc-2023-008482 · 2024 · External reference
Targeting IL-17A to combat immune-related adverse events.
10.1038/s43018-024-00804-2 · 2024 · External reference
IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy.
10.1158/2326-6066.cir-18-0682 · 2019 · External reference
Immune-related adverse events of immune checkpoint inhibitors: a review.
10.3389/fimmu.2023.1167975 · 2023 · External reference
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
10.1038/s41586-019-1162-y · 2019 · External reference
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.
10.1186/s40425-018-0412-0 · 2018 · External reference
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
10.1038/s41591-025-04158-9 · 2026 · External reference
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model.
10.1038/s41467-019-08352-5 · 2019 · External reference
